HPP-971 is under clinical development by Anteris Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect HPP-971’s likelihood of approval (LoA) and phase transition for Inflammation took place on 05 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HPP-971 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

HPP-971 overview

HPP-971 is under development for the treatment of inflammatory disorders associated with oxidative stress and non-alcoholic steatohepatitis (NASH) and renal diseases. It is administered through oral route. The drug candidate is a small molecule, which acts by targeting Bach1 and Nrf2. It is developed based on using TTP translational technology. It was also under development for the treatment of renal atrophy, hypertension, diabetes, autoimmune diseases and obesity.

Quick View HPP-971 LOA Data

Report Segments
  • Innovator
Drug Name
  • HPP-971
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Metabolic Disorders
Key Developers
  • Sponsor Company: Anteris Bio
  • Originator: vTv Therapeutics
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.